Pancreatic: Metastatic: 1st Line: NAPOLI 3
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Title
Ipsen D-US-60010-001 (Pancreatic)
Study Title
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Site Link
Malignancy
Pancreas Adenocarcinoma
Stage
Disease Setting
Metastatic/Palliative
Line Of Therapy
1st
Investigational Agent
Irinotecan liposome injection (Nal-IRI)
Drug Class
Liposomal chemotherapy
PI
Axel Grothey, MD
Sponsor
Ipsen
Phase
Status
Key Eligibility Criteria Details
- Histologically confirmed adenocarcinoma of pancreas not previously treated in metastatic setting
- Initial diagnosis of metastatic disease < or = 6 weeks prior to screening
- Measurable disease
- ECOG PS 0-1
- Adequate hepatic, hemtologic, and renal function
- No prior therapy in adjuvant setting unless adjuvant therapy was completed at least 12 months prior to metastatic diagnosis
- No CNS metastases
Objective
- Primary- OS
- Secondary- PFS, ORR
Assessment Frequency
_
Assessment Frequency 2
_